查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1351045

2030 年伴隨診斷市場預測：按產品、適應症、技術、最終用戶和地區進行的全球分析

Companion Diagnostics Market Forecasts to 2030 - Global Analysis By Product, Indication, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球伴隨診斷市場規模為 72.4 億美元，預計到 2030 年將達到 188.1 億美元，預測期內年複合成長率為 14.6%。

伴隨診斷是用於確保可比較生物製劑或藥物的使用安全有效的測試。這些檢查通常用於診斷癌症、神經系統疾病、心血管疾病和感染疾病。此測試根據檢測到的生物標記推薦適當的藥物。根據特定患者的反應，這些測試提供量身定做的治療。在決定是否使用標靶治療藥物時，伴隨診斷測試（CDX）至關重要。

根據肺癌研究基金會2022年報告，預計2022年美國將有236,740人被診斷出患有肺癌，增加了對肺癌伴隨診斷的需求。

對專業治療的需求不斷增加

隨著基因定序和基因組學的進步，人們普遍認為不同的個體可能會對不同的藥物產生反應。透過更了解一個人的遺傳特徵和生物標記物，我們可以改進技術，在正確的時間、以正確的劑量向正確的人給藥正確的藥物。為了將治療給藥放在正確的候選人身上，製藥和生物製藥公司繼續努力在藥物開發的早期階段採用患者選擇性診斷框架。這有助於市場的進一步擴大。

付款不足的例子

儘管人們越來越認知到伴隨診斷的效用，但尚未建立伴隨診斷支付的標準。付款方式依具體情況決定。住院治療和門診治療的醫療費用是不同的。診斷主要由診斷相關團體負責住院治療系統。門診護理費用是根據可報銷服務的詳細清單支付的。結果，缺乏補償和嚴格的監管限制了市場的擴張。

患病盛行率增加

胰臟癌、女性乳癌和大腸直腸癌新發病例的增加，以及骨髓瘤、子宮癌和腎癌的停滯，是由於肥胖、糖尿病和缺乏運動的患病上升。事實證明，伴隨診斷不僅在臨床個別患者的治療中，而且在新藥開發過程中都是至關重要的工具。從伴隨診斷中獲得的資訊對於安全有效地使用標靶藥物至關重要。這項診斷有幾個雄心勃勃的目標。由於有效的診斷、監測、篩檢和預後預測，市場正在擴大。

免疫治療費用高

儘管免疫療法是一種非常有前景的癌症治療方法，但其高昂的成本限制了一般患者的使用。如果您的醫師確定合併用藥有益，治療時間可能會從 5 個月延長到 3 年以上。在這種情況下，治療時間越長，費用就越高。每種 CAR T 細胞療法都是針對每位患者量身定做的，並且需要大量的研究資源。因此，僅每位患者的藥品費用就上升至約 6 萬美元。癌症免疫療法可能比化療和放射線治療等其他治療方法昂貴得多。因此，免疫腫瘤治療的高成本預計將限制其擴張。

COVID-19 的影響：

COVID-19 的早期檢測在市場上至關重要，因為它可能會導致適當的治療。使用鼻咽拭子或其他上呼吸道檢體（包括咽喉拭子）進行聚合酶連鎖反應 (PCR) 檢測，是診斷 COVID-19 時使用最廣泛、最可靠的方法。自此，基於聚合酶鏈反應（PCR）的診斷方法成為治療該疾病的重要領域。市場成長的推動因素包括針對各種疾病的新生物標記的開發、標靶治療的研發不斷增加、新興市場意識的提高對個人化醫療的需求增加以及未滿足的醫療需求不斷增加，這是要素。

腫瘤學領域預計在預測期內規模最大

隨著全球範圍內肺癌患病率的增加，患病領域預計將出現良好的成長。在決定是否使用標靶治療藥物治療肺癌時，伴隨診斷測試（CDX）被認為是必不可少的。在初始治療中接受伴隨測試的肺癌患者比未接受篩檢的患者有更高的存活率。非小細胞肺癌（NSCLC）患病的不斷上升以及針對該疾病的腫瘤學伴隨診斷的加速發展預計將推動該領域在全球範圍內的成長。

聚合酶鏈反應（PCR）領域預計在預測期內年複合成長率最高

聚合酶鏈反應（PCR）領域預計在預測期內年複合成長率最快。高靈敏度 PCR 方法可以快速擴增 DNA 的特定部分。 PCR 使用基於大小和電荷的視覺方法，可以透過產生數十億個特定 DNA 片段或基因的拷貝來檢測和鑒定基因序列。這是一項快速診斷測試，可在 4 至 8 小時內完成。由於更快的結果、有效的適當治療和抗菌藥物抗藥性測試，這一類別正在不斷成長。

比最大的地區

預計北美在預測期內將佔據最大的市場佔有率。美國已成為該地區的主要貢獻者。美國開始在該地區發揮重要作用。在美國，伴隨診斷最常見的使用者是慢性病患者。隨著該地區使用伴隨診斷試劑盒的研究活動的增加，以及為了解人類基因組而創建的基因資料庫的醫療機構數量也在增加，該市場正在擴大。

複合年複合成長率最高的地區：

由於對個人化醫療的偏好以及公司之間合作的增加，預計歐洲在預測期內將呈現最高的年複合成長率。德國和法國在該地區的市場佔有率最高。該地區不斷發展的醫療旅遊業，以及越來越多的老年人口（更容易患癌症和神經系統疾病）正在進一步推動市場需求。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球伴隨診斷市場：按產品

  • 試劑盒/試劑
  • 化驗

第6章 全球伴隨診斷市場：依徵兆分類

  • 白血病
  • 黑色素瘤
  • 癌症
    • 肺癌
    • 乳癌
    • 血癌
    • 大腸直腸癌
    • 其他
  • 神經系統疾病
  • 心血管疾病
  • 感染疾病
  • 其他

第7章 全球伴隨診斷市場：依技術分類

  • 即時螢光定量PCR (RT-PCR)
  • 聚合酶鍊式反應 (PCR)
  • 次世代定序
  • 原位雜合技術 (ISH)
  • 免疫組織化學 (IHC)
  • 基因定序
  • 其他

第8章 全球伴隨診斷市場：依最終用戶分類

  • 委外研發機構（CRO）
  • 製藥公司/生物製藥公司
  • 參考實驗室
  • 其他

第9章 全球伴隨診斷市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Abbott
  • Agendia NV
  • Agilent Technologies
  • ARUP Laboratories, Inc.
  • Biogenex Laboratories, Inc.
  • Dako, Inc.
  • Roche Molecular Systems, Inc.
  • Thermo Fisher Scientific
  • GE Healthcare
  • Genomic Health
  • Illumina, Inc.
  • Genetron Holdings Limited
  • Labcorp Drug Development
  • Leica Biosystems
  • Life Technologies Corporation
  • MolecularMD Corporation
  • Myriad Genetic Laboratories, Inc.
  • Ventana Medical Systems, Inc.
  • Exact Sciences Corporation
  • Qiagen
Product Code: SMRC23732

According to Stratistics MRC, the Global Companion Diagnostics Market is accounted for $7.24 billion in 2023 and is expected to reach $18.81 billion by 2030 growing at a CAGR of 14.6% during the forecast period. A companion diagnostic is a test used to ensure the usage of a comparable biological product or medication is both safe and effective. These tests are typically used to diagnose cancer, neurological, cardiovascular and infectious diseases. In this, an appropriate medicine is recommended based on the detected biomarker. Based on a particular patient's reaction, these tests offer tailored treatment. When deciding whether to use targeted therapeutics, companion diagnostic exams (CDXs) are crucial.

According to Lung Cancer Research Foundation report 2022, an estimated 236,740 people were diagnosed with lung cancer in 2022 in the United States, leading to more demand for lung cancer companion diagnostics.

Market Dynamics:

Driver:

Growing requirements for specialized treatments

Since genetic sequencing and genomics have advanced, it is generally accepted that various individuals might respond to medications differently. The technique of giving "the right drug, at the right time, at the right dose, for the right person" can be advanced by having a better understanding of a person's genetic traits or biomarkers. In order to give focused therapeutics to the appropriate candidate, pharmaceutical and biopharmaceutical firms are continually working to adopt patient-selection diagnostic frameworks in the early phases of drug development. This helps the market's expansion to grow further.

Restraint:

The instance for insufficient reimbursement

Despite growing acceptability, there are no established criteria for determining how much should be paid for a companion diagnostic test. Payment is determined on a case-by-case basis. For inpatient and outpatient care, reimbursement is different. Diagnostics are primarily covered for the inpatient care system by diagnosis-related groups. The payment is made in accordance with the detailed list of services that can be reimbursed for outpatient care. Therefore, the absence of compensation and onerous rules restrain market expansion.

Opportunity:

Increasing prevalence of cancer

The increased trends in new instances of pancreatic, female breast, and colorectal cancer as well as the stagnation of myeloma, uterine, and kidney cancer are attributed to the rising prevalence of obesity, diabetes, and physical inactivity. Companion diagnostics have proven to be a crucial tool for the treatment of individual patients in the clinic as well as for the process of developing new drugs. Information from companion diagnostics is crucial for the safe and efficient use of targeted medicines. This diagnosis has several ambitious objectives. The market is growing because of its effective diagnosis, monitoring, screening, and prognosis.

Threat:

High cost of immunotherapy treatment

The high expense of immunotherapy has restricted general patient access even though it has showed tremendous promise in the treatment of cancer. The length of the course of therapy might be increased from five months to over three years if doctors decide that it is beneficial to combine medicines. In this instance, the cost increases as the duration increases. Each CAR T-cell therapy is customized for the patient, requiring significant lab resources. As a result, the price per patient for the medicine alone rises to around USD 60,000. Cancer immune therapies can be far more expensive than other treatment choices like chemotherapy or radiation therapy. Consequently, it is anticipated that the high cost of immune-oncology treatments would restrain their expansion.

COVID-19 Impact:

Early detection of COVID-19 became crucial in the market since it may aid in people with the condition receiving the right care. The polymerase chain reaction (PCR) test employing nasopharyngeal swabs or other upper respiratory tract specimens, including throat swabs, was the most widely used and trustworthy method for the diagnosis of COVID-19. Polymerase chain reaction (PCR)-based diagnostics, then, became a key area of focus for treating the illness. The development of new biomarkers for various diseases, an increase in research and development of targeted therapies, an increase in demand for customized medicine with increased recognition in developing markets, and a higher number of unmet medical needs are all contributing factors fuelled the market growth.

The cancer segment is expected to be the largest during the forecast period

The cancer segment is estimated to have a lucrative growth, due to the growing prevalence of lung cancer all around the world. When deciding whether to use targeted medicines to treat lung cancer, companion diagnostic tests (CDXs) are regarded as indispensable. Lung cancer patients who obtained companion diagnostics as part of their initial treatment had higher survival rates than patients who did not get screened. The increasing prevalence of non-small cell lung cancer (NSCLC), together with the acceleration of the development of oncology companion diagnostic tests for the condition, are expected to propel the segment's growth on a global scale.

The polymerase chain reaction (PCR) segment is expected to have the highest CAGR during the forecast period

The polymerase chain reaction (PCR) segment is anticipated to witness the fastest CAGR growth during the forecast period. The highly sensitive PCR method enables quick DNA amplification of a particular section. Using visual methods based on size and charge, PCR may detect and identify gene sequences by producing billions of copies of a certain DNA fragment or gene. It is a rapid diagnostic exam that takes 4 to 8 hours to complete. The category is growing as a consequence of its speedier results, efficient appropriate therapy, and anti-microbial resistance testing.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. United States is emerging as a major contributor in the region. The United States has begun to play a significant role in this region. The most common users of companion diagnostics in the US are those with chronic diseases. The market is expanding as a result of rising research activities employing companion diagnostic kits in this region as well as the rising number of healthcare organizations working on genomic databases created to comprehend the human genome.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the growing preference for personalized medicine and increasing collaboration among companies. The region's highest market share is held by Germany and France. The market demand is being further fuelled by the region's growing medical tourism industry as well as the region's expanding senior population who are more susceptible to cancer and neurological illnesses.

Key players in the market:

Some of the key players profiled in the Companion Diagnostics Market include: Abbott, Agendia N.V, Agilent Technologies, ARUP Laboratories, Inc., Biogenex Laboratories, Inc., Dako, Inc., Roche Molecular Systems, Inc., Foundation Medicine, Inc., GE Healthcare, Genomic Health, Illumina, Inc., Genetron Holdings Limited, Labcorp Drug Development, Leica Biosystems, Life Technologies Corporation, MolecularMD Corporation, Myriad Genetic Laboratories, Inc., Ventana Medical Systems, Inc., Exact Sciences Corporation and Qiagen.

Key Developments:

In January 2023, Thermo Fisher Scientific partners with Astrazeneca to develop solid tissue and blood-based companion diagnostic test for tagrisso. The collaboration will leverage the Oncomine Dx Express Test* on the Genexus Dx System*, a fully-integrated next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that economically delivers results in as little as 24 hours to bring test results to clinicians and patients faster.

In February 2022, Genetron Holdings Limited, a leading precision oncology platform company in China specializing in molecular profiling tests, early cancer screening products, and companion diagnostics development, entered a collaboration agreement with HUTCHMED (China) Limited to develop a companion diagnostic (CDx).

Products Covered:

  • Kits & Reagents
  • Assays

Indications Covered:

  • Leukaemia
  • Melanoma
  • Cancer
  • Neurological Disorders
  • Cardiovascular Diseases
  • Infectious Diseases
  • Other Indications

Technologies Covered:

  • Real-time PCR (RT-PCR)
  • Polymerase Chain Reaction (PCR)
  • Next-generation Sequencing
  • In Situ Hybridization (ISH)
  • Immunohistochemistry (IHC)
  • Gene Sequencing
  • Other Technologies

End Users Covered:

  • Contract Research Organizations
  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Companion Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Kits & Reagents
  • 5.3 Assays

6 Global Companion Diagnostics Market, By Indication

  • 6.1 Introduction
  • 6.2 Leukaemia
  • 6.3 Melanoma
  • 6.4 Cancer
    • 6.4.1 Lung Cancer
    • 6.4.2 Breast Cancer
    • 6.4.3 Blood Cancer
    • 6.4.4 Colorectal Cancer
    • 6.4.5 Other Cancer Types
  • 6.5 Neurological Disorders
  • 6.6 Cardiovascular Diseases
  • 6.7 Infectious Diseases
  • 6.8 Other Indications

7 Global Companion Diagnostics Market, By Technology

  • 7.1 Introduction
  • 7.2 Real-time PCR (RT-PCR)
  • 7.3 Polymerase Chain Reaction (PCR)
  • 7.4 Next-generation Sequencing
  • 7.5 In Situ Hybridization (ISH)
  • 7.6 Immunohistochemistry (IHC)
  • 7.7 Gene Sequencing
  • 7.8 Other Technologies

8 Global Companion Diagnostics Market, By End User

  • 8.1 Introduction
  • 8.2 Contract Research Organizations
  • 8.3 Pharmaceutical & Biopharmaceutical Companies
  • 8.4 Reference Laboratories
  • 8.5 Other End Users

9 Global Companion Diagnostics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott
  • 11.2 Agendia N.V
  • 11.3 Agilent Technologies
  • 11.4 ARUP Laboratories, Inc.
  • 11.5 Biogenex Laboratories, Inc.
  • 11.6 Dako, Inc.
  • 11.7 Roche Molecular Systems, Inc.
  • 11.8 Thermo Fisher Scientific
  • 11.9 GE Healthcare
  • 11.10 Genomic Health
  • 11.11 Illumina, Inc.
  • 11.12 Genetron Holdings Limited
  • 11.13 Labcorp Drug Development
  • 11.14 Leica Biosystems
  • 11.15 Life Technologies Corporation
  • 11.16 MolecularMD Corporation
  • 11.17 Myriad Genetic Laboratories, Inc.
  • 11.18 Ventana Medical Systems, Inc.
  • 11.19 Exact Sciences Corporation
  • 11.20 Qiagen

List of Tables

  • Table 1 Global Companion Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Companion Diagnostics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Companion Diagnostics Market Outlook, By Kits & Reagents (2021-2030) ($MN)
  • Table 4 Global Companion Diagnostics Market Outlook, By Assays (2021-2030) ($MN)
  • Table 5 Global Companion Diagnostics Market Outlook, By Indication (2021-2030) ($MN)
  • Table 6 Global Companion Diagnostics Market Outlook, By Leukaemia (2021-2030) ($MN)
  • Table 7 Global Companion Diagnostics Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 8 Global Companion Diagnostics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 9 Global Companion Diagnostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 10 Global Companion Diagnostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 11 Global Companion Diagnostics Market Outlook, By Blood Cancer (2021-2030) ($MN)
  • Table 12 Global Companion Diagnostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 13 Global Companion Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 14 Global Companion Diagnostics Market Outlook, By Neurological Disorders (2021-2030) ($MN)
  • Table 15 Global Companion Diagnostics Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 16 Global Companion Diagnostics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 17 Global Companion Diagnostics Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 18 Global Companion Diagnostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 19 Global Companion Diagnostics Market Outlook, By Real-time PCR (RT-PCR) (2021-2030) ($MN)
  • Table 20 Global Companion Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 21 Global Companion Diagnostics Market Outlook, By Next-generation Sequencing (2021-2030) ($MN)
  • Table 22 Global Companion Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2021-2030) ($MN)
  • Table 23 Global Companion Diagnostics Market Outlook, By Immunohistochemistry (IHC) (2021-2030) ($MN)
  • Table 24 Global Companion Diagnostics Market Outlook, By Gene Sequencing (2021-2030) ($MN)
  • Table 25 Global Companion Diagnostics Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 26 Global Companion Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Companion Diagnostics Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 28 Global Companion Diagnostics Market Outlook, By Pharmaceutical & Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 29 Global Companion Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
  • Table 30 Global Companion Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.